Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
about
Therapeutic drug monitoring for triazoles: A needs assessment review and recommendations from a Canadian perspectiveAntifungal Prophylaxis in Immunocompromised PatientsAntifungal Therapy in Hematopoietic Stem Cell Transplant RecipientsSystematic review and mixed treatment comparison meta-analysis of randomized clinical trials of primary oral antifungal prophylaxis in allogeneic hematopoietic cell transplant recipientsDrug safety data mining with a tree-based scan statistic.Organ-specific management and supportive care in chronic graft-versus-host disease.Treatment of febrile neutropenia and prophylaxis in hematologic malignancies: a critical review and update.Population pharmacokinetics of voriconazole in adultsIncidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort studyPharmacodynamics of itraconazole against Aspergillus fumigatus in an in vitro model of the human alveolus: perspectives on the treatment of triazole-resistant infection and utility of airway administration.Use of antifungal drugs in hematologyPrimary antifungal prophylaxis during curative-intent therapy for acute myeloid leukemia.Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection ProphylaxisRisk factors and impact of non-Aspergillus mold infections following allogeneic HCT: a CIBMTR infection and immune reconstitution analysis.Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO).Therapeutic drug monitoring (TDM) of antifungal agents: guidelines from the British Society for Medical Mycology.Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice.Pharmacotherapy approaches to antifungal prophylaxis.Safety and interactions of new antifungals in stem cell transplant recipients.Using antimicrobial adjuvant therapy in cancer treatment: a review.Voriconazole in clinical practice.Second- versus first-generation azoles for antifungal prophylaxis in hematology patients: a systematic review and meta-analysis.Voriconazole and its clinical potential in the prophylaxis of systemic fungal infection in patients with hematologic malignancies: a perspective reviewAllogeneic transplantation in the UK: an aggregation of marginal gains?Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology.Update on epidemiology of and preventive strategies for invasive fungal infections in cancer patients.Anti-infective prophylaxis in pediatric patients with acute myeloid leukemia.Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014.Invasive fungal infections: managing the continuum of risk in HCT patients.Early diagnosis of invasive mould infections and disease.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Aspergillosis of the Heart and Lung and Review of Published Reports on Fungal Endocarditis.Aspergillosis and stem cell transplantation: An overview of experimental pathogenesis studies.Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis.Voriconazole for prophylaxis of invasive fungal infections after allogeneic hematopoietic stem cell transplantation.Liposomal amphotericin B (AmBisome®) at beginning of its third decade of clinical use.Voriconazole pharmacokinetics following HSCT: results from the BMT CTN 0101 trial.Clinical considerations in the early treatment of invasive mould infections and disease.Infectious Risk after Allogeneic Hematopoietic Cell Transplantation Complicated by Acute Graft-versus-Host Disease.Risk factors and prophylaxis against invasive fungal disease for haematology and stem cell transplant recipients: an evolving field.
P2860
Q27009221-281D0987-50D4-4D17-9C5D-E40875F4C88AQ28074168-E994A614-914B-41A9-B596-9FAA4214BB9CQ28080147-2F676F09-6A4B-4E47-A999-DD2F00387580Q28083874-81C71B8E-4E18-4613-B5D0-716F6C92FE7CQ30604219-DBC689F6-75BB-4F10-970F-A8FB3D2F1B32Q34270868-4F424576-2A3A-499F-8A01-952D5FF558DAQ34667166-4B79A82F-6638-48ED-9287-630FAFA1A4D3Q35666490-3D499A99-86C2-4438-9536-49CBE6B78E92Q35881360-427A0270-C531-41B6-8823-2F876F008A51Q36171643-F287D557-1116-4639-AA76-E3F89D910428Q36364856-44006F22-0F92-41F8-84C1-8EC2FA6B386BQ36406975-99293776-C9E2-4D2C-9118-029941D07965Q36439034-31F8ED46-0902-461B-9FD7-FDAA1D5EF042Q36540732-6483F1DF-41C3-4BE1-BAC7-BC535F0992E4Q37469829-9A27B6EA-832C-4575-A852-CE15191B0890Q37688257-C64192C1-CDF8-4188-80A8-E42E3E7DA291Q37993110-C61D1932-CCA6-4D2C-BE0D-6A280C5C0150Q38020238-C264D4DA-1002-471B-8A03-8A40A5FD3166Q38036740-5B8318B8-6672-4744-92A9-20B8C4E42218Q38060894-E55A7D0E-A46C-475B-B93F-B3315C8234B9Q38061736-8FE9AEDA-6504-433A-B3CC-7CB0AD2FDC09Q38086013-121F7AFE-4025-4B1F-A29B-2E9AB4C7413FQ38111391-B659897B-7B00-4ED3-8408-22E4BFEABA81Q38124363-9BC64F1D-F7B6-4EE0-B674-9BE1A5F790E4Q38222029-012B796B-71D7-4589-B625-69527803AFECQ38263489-2F00B6B9-A6B1-4489-9535-77AB1CA63DB9Q38264086-85D713E5-FBE2-4EE6-82F4-EA9BD0DBEA99Q38284455-E7C51108-E242-4AEE-BE77-56AE3939873AQ38661492-8C51F8D2-EB98-4241-84E6-507A06B652FFQ38738085-87D7ABF4-4BE1-4502-823D-D62C6D5EAB68Q38738090-A9D30AFE-4D94-428E-9383-3C6B704EB234Q38849156-251087A7-16E4-495E-BDCE-6460A9B30CDDQ38968506-25897CC1-A6E7-46FC-8E27-AB2D10268E4BQ39195902-2ECCBD0E-3523-40BB-B82F-395955F30696Q39196770-DF10A295-E82E-48B7-A2CE-E259A3195F83Q39196802-2A7EC454-9983-4C64-83D3-2F30339A427DQ39816665-22B77BA6-75B5-4F4C-8243-946357E57725Q40063394-4B4206C7-1A48-46D9-9678-DC87A12FCF89Q40395771-4A103802-3D92-4176-93C3-8F7D8ACADDCBQ40515140-B5E5E66E-7C4F-40A4-963C-8DAF278C024A
P2860
Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Voriconazole versus itraconazo ...... tic stem-cell transplantation.
@ast
Voriconazole versus itraconazo ...... tic stem-cell transplantation.
@en
type
label
Voriconazole versus itraconazo ...... tic stem-cell transplantation.
@ast
Voriconazole versus itraconazo ...... tic stem-cell transplantation.
@en
prefLabel
Voriconazole versus itraconazo ...... tic stem-cell transplantation.
@ast
Voriconazole versus itraconazo ...... tic stem-cell transplantation.
@en
P2093
P2860
P1476
Voriconazole versus itraconazo ...... tic stem-cell transplantation.
@en
P2093
Axel Glasmacher
Carlos Solano
Christopher C Kibbler
Claus-Peter Heussel
David I Marks
Gordon Cook
Haran T Schlamm
IMPROVIT Study Group
Michal Kantecki
Patricia Ribaud
P2860
P304
P356
10.1111/J.1365-2141.2011.08838.X
P407
P577
2011-08-22T00:00:00Z